Northland Securities Has Positive View of HRTX Q3 Earnings

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Analysts at Northland Securities boosted their Q3 2026 EPS estimates for Heron Therapeutics in a note issued to investors on Thursday, March 26th. Northland Securities analyst C. Byrnes now anticipates that the biotechnology company will post earnings per share of $0.00 for the quarter, up from their previous forecast of ($0.01). The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.13) per share. Northland Securities also issued estimates for Heron Therapeutics’ Q4 2026 earnings at $0.01 EPS.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.01. The firm had revenue of $40.59 million during the quarter, compared to analysts’ expectations of $39.53 million.

Several other analysts have also recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Heron Therapeutics in a research report on Friday, January 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Thursday, January 22nd. Finally, Zacks Research downgraded Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, February 26th. Three research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $4.50.

Heron Therapeutics Price Performance

Shares of NASDAQ:HRTX opened at $0.78 on Friday. The company’s fifty day moving average is $1.13 and its two-hundred day moving average is $1.21. The company has a quick ratio of 1.51, a current ratio of 2.48 and a debt-to-equity ratio of 10.59. Heron Therapeutics has a 12-month low of $0.75 and a 12-month high of $2.61. The company has a market cap of $147.76 million, a P/E ratio of -6.03 and a beta of 1.26.

Institutional Investors Weigh In On Heron Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP acquired a new position in shares of Heron Therapeutics in the third quarter worth $5,357,000. Citigroup Inc. boosted its position in Heron Therapeutics by 4,666.9% during the third quarter. Citigroup Inc. now owns 2,476,529 shares of the biotechnology company’s stock valued at $3,120,000 after purchasing an additional 2,424,576 shares during the last quarter. JW Asset Management LLC boosted its position in Heron Therapeutics by 40.8% during the third quarter. JW Asset Management LLC now owns 3,292,633 shares of the biotechnology company’s stock valued at $4,149,000 after purchasing an additional 954,890 shares during the last quarter. New York State Common Retirement Fund grew its stake in Heron Therapeutics by 46.4% in the third quarter. New York State Common Retirement Fund now owns 2,576,716 shares of the biotechnology company’s stock valued at $3,247,000 after purchasing an additional 816,671 shares in the last quarter. Finally, Jefferies Financial Group Inc. grew its stake in Heron Therapeutics by 106.7% in the second quarter. Jefferies Financial Group Inc. now owns 666,800 shares of the biotechnology company’s stock valued at $1,380,000 after purchasing an additional 344,200 shares in the last quarter. Hedge funds and other institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.